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Background. Qatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that dispropor-
tionately affected the craft and manual worker (CMW) population, who comprise 60% of the total population. This study aimed to 
assess ever and/or current infection prevalence in this population.
Methods. A cross-sectional population-based survey was conducted during July 26 to September 09, 2020, to assess both anti-
SARS-CoV-2 positivity through serological testing and current infection positivity through polymerase chain reaction (PCR) testing. 
Associations with antibody and PCR positivity were identified through regression analyses.
Results. The study included 2641 participants, 69.3% of whom were <40 years of age. Anti-SARS-CoV-2 positivity was 55.3% (95% 
CI, 53.3%–57.3%) and was significantly associated with nationality, geographic location, educational attainment, occupation, and previous 
infection diagnosis. PCR positivity was 11.3% (95% CI, 9.9%–12.8%) and was significantly associated with nationality, geographic location, 
occupation, contact with an infected person, and reporting 2 or more symptoms. Infection positivity (antibody and/or PCR positive) was 
60.6% (95% CI, 58.6%–62.5%). The proportion of antibody-positive CMWs who had a prior SARS-CoV-2 diagnosis was 9.3% (95% CI, 
7.9%–11.0%). Only seven infections were ever severe, and only 1 was ever critical—an infection severity rate of 0.5% (95% CI, 0.2%–1.0%).
Conclusions. Six in every 10 CMWs in Qatar have been infected, suggestive of reaching the herd immunity threshold. Infection 
severity was low, with only 1 in every 200 infections progressing to be severe or critical. Only 1 in every 10 infections had been pre-
viously diagnosed, which is suggestive of mostly asymptomatic or mild infections.
Keywords.  COVID-19; immunity; Qatar; SARS-CoV-2; seroprevalence.
The severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection has spread worldwide, causing disease and 
mortality as well as social and economic disruptions [1–3]. 
Qatar, a country in the Arabian Gulf, has experienced a per-
vasive epidemic, with >55 000 laboratory-confirmed infections 
per million population as of November 20, 2020 [4, 5].
Most affected by the epidemic were the expatriate craft and 
manual workers (CMWs) who comprise 60% of the popula-
tion of Qatar [6]. These workers are typically single men aged 
20–49  years, recruited to work in development projects, and 
living in large shared accommodations [6–9]. Epidemiologic data 
on this population have indicated large SARS-CoV-2 outbreaks 
[7, 10, 11] that resembled those in nursing homes [12–14] or in-
fluenza outbreaks in regular and boarding schools [15, 16].
This study aimed to assess ever and current infection with 
SARS-CoV-2, the infection severity rate, and the infection di-
agnosis (detection) rate in the wider CMW population of Qatar.
METHODS
Study Design and Sampling
A national cross-sectional survey was conducted between 
July 26 and September 9, 2020, to assess anti-SARS-CoV-2 
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(antibody) positivity and SARS-CoV-2 polymerase chain re-
action (PCR) positivity among CMWs in Qatar. To optimize 
sample representativeness of the wider CMW population in 
the absence of a comprehensive listing for CMWs, we devised 
a sampling strategy based on analysis of the registered users’ 
database of the Qatar Red Crescent Society (QRCS), the main 
provider of primary health care for CMWs in the country. 
QRCS operates 4 geographically distributed centers that were 
specifically designed to cater to the CMW population across the 
country. These centers were established over a decade ago and 
are well known by CMWs, operate long working hours (3 run 
>24 hours and 1 runs >16 hours), are located in regions where 
workers live, and provide services that are free of charge or 
heavily subsidized for enhanced accessibility and affordability. 
The probability distribution of CMWs by age and nationality in 
the QRCS database was cross-checked and found to be similar 
to that of the Ministry of Interior database of expatriate resi-
dents [8]. Sex was not considered in the sampling strategy be-
cause the vast majority of CMWs (>99%) are men [6].
The overall sample size was determined at 2232 assuming a 
seroprevalence of 25% (given the large epidemic in Qatar [7, 
11]), a margin of error of 2%, and a nonresponse rate of 15%, 
but was increased to 2658 to ensure that a minimum of 5 indi-
viduals were recruited per each age–nationality stratum from 
each center (for better representation of small groups).
Due to time constraints and operational challenges in di-
rectly contacting the CMWs and recruiting them, recruitment 
was implemented per the above sampling strategy but using 
systematic sampling of the attendees at these centers during the 
study duration. By factoring the average number of attendees 
per day at each of these centers, every fourth attendee visiting 
each center was invited to participate in this study until the 
sample size by age and nationality at each center was fulfilled. 
It was difficult to recruit participants in the small age–nation-
ality strata (such as among younger persons for specific nation-
alities), and thus toward the end of the study all attendees in 
these strata (not only every fourth attendee) were approached 
to participate.
Patient Consent Statement
A written informed consent was collected from all study partici-
pants. The study was approved by Hamad Medical Corporation 
(HMC) and Weill Cornell Medicine-Qatar Institutional Review 
Boards.
Sample Collection and Handling
An interview schedule inquiring about sociodemographics 
and history of exposure and symptoms was administered by 
trained interviewers in the participant’s language of prefer-
ence. Both informed consent and interview schedule were 
provided and collected in 9 languages (Arabic, Bengali, 
English, Hindi, Nepali, Sinhala, Tagalog, Tamil, and Urdu) 
to cater to the main language groups of CMWs. The study 
instrument was based on a protocol for SARS-CoV-2 sero-
epidemiological surveys developed by the World Health 
Organization (WHO) [17]. Blood (10 mL) was drawn for se-
rological testing by certified nurses and stored in an ice box 
before being transported to the HMC Central Laboratory for 
analysis. Nasopharyngeal and oropharyngeal swabs were also 
collected by the nurses to assess current infection. National 
guidelines and standard of care were applied to all identi-
fied PCR-positive cases. No action was mandated by national 
guidelines to those found antibody positive.
Laboratory Methods
Testing for SARS-CoV-2-specific antibodies in the serological 
samples was performed using an electrochemiluminescence 
immunoassay, the Roche Elecsys Anti-SARS-CoV-2 (99.5% 
sensitivity [18], 99.8% specificity [18, 19]; Roche, Switzerland). 
Interpretation of results was per the manufacturer’s instructions: 
reactive for optical density cutoff index ≥1.0 and nonreactive 
for cutoff index <1.0 [19].
PCR testing was performed on aliquots of Universal 
Transport Medium (UTM) used for collection of nasopha-
ryngeal swabs (Huachenyang Technology, Shenzen, China). 
Aliquots were extracted on the QIAsymphony platform 
(QIAGEN, Germantown, Maryland, USA) and tested with real-
time reverse transcription PCR (RT-qPCR) using the TaqPath 
COVID-19 Combo Kit (100% sensitivity and specificity [20]; 
Thermo Fisher Scientific, Waltham, Massachusetts, USA) on 
an ABI 7500 FAST (Thermo Fisher, Waltham, Massachusetts, 
USA), extracted using a custom protocol [21] on a Hamilton 
Microlab STAR (Hamilton, Reno, Nevada, USA), and tested 
using the AccuPower SARS-CoV-2 Real-Time RT-PCR Kit 
(100% sensitivity and specificity [22]; Bioneer, Daejeon, Korea) 
on an ABI 7500 FAST or loaded directly into the Roche cobas 
6800 system and assayed with the cobas SARS-CoV-2 Test (95% 
sensitivity, 100% specificity [23]; Roche, Basel, Switzerland).
All laboratory testing was conducted at the HMC Central 
Laboratory following standardized protocols.
Statistical Analysis
Frequency distributions were used to characterize study par-
ticipants. Absence/presence of symptoms in the 2 weeks pre-
ceding the survey (no symptoms, 1 symptom, and 2 or more 
symptoms) was defined using a composite index score derived 
by summing up the values for reported symptoms coded as 
“0” for absence and “1” for presence. Probability weights were 
applied to adjust for participants’ unequal selection using the 
CMW population distribution by age group and nationality per 
the QRCS registered-user database.
Associations with anti-SARS-CoV-2 positivity were explored 
using the chi-square test and univariable logistic regression ana-
lyses. Covariates with P values ≤.2 in the univariable regression 
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analysis were included in the multivariable model. Covariates 
with P values ≤.05 in the multivariable analysis were considered 
as showing statistically significant evidence for an association 
with the outcome. Odds ratios (ORs), adjusted ORs (AORs), 
95% CIs, and P values were reported. Associations with PCR 
positivity were also explored following the above-described 
methodology.
Antibody test results were subsequently linked to the national 
SARS-CoV-2 PCR testing and COVID-19 hospitalization and 
severity database, which includes all PCR testing, hospitaliza-
tion, and SARS-CoV-2 infection severity classifications, as per 
the WHO criteria [24], since the start of the epidemic. Relevant 
epidemiological measures such as prevalence of ever and/or 
current infection, infection severity rate, and infection diag-
nosis rate were derived.
RESULTS
The final study sample included 2641 participants (Table 1), 
with a median age (range) of 35 (18–80) years. Most partici-
pants were below 40 years of age (69.3%) and of Indian (29.2%), 
Bangladeshi (26.2%), or Nepalese (21.6%) origin, representative 
of the wider CMW population in Qatar [8]. More than 40% had 
intermediate or lower educational attainment, and another 40% 
attended high school or vocational training. Over half of the 
sample consisted of technical and construction workers such 
as carpenters, crane operators, electricians, foremen, mainte-
nance/air conditioning/cable technicians, masons, mechanics, 
painters, pipe fitters, plumbers, and welders, while 4.8% held 
higher professional positions such as architects, designers, en-
gineers, operation managers, and supervisors.
A total of 1427 participants had detectable SARS-CoV-2 
antibodies—a seropositivity of 55.3% (95% CI, 53.3%–57.3%) 
(Table 1). Seropositivity was independently associated with 
each of nationality, QRCS center (proxy of catchment area/ge-
ographic location), educational attainment, occupation, and 
previous infection diagnosis in the multivariable regression 
analysis (Table 1). Still, the differences in seropositivity were 
overall not considerable, apart from those by nationality, occu-
pation, and geographic location (QRCS center). Compared with 
all other nationalities, the AOR was 0.41 (95% CI, 0.20–0.85) for 
Filipinos, 1.83 (95% CI, 1.17–2.87) for Nepalese, and 3.05 (95% 
CI, 1.93–4.80) for Bangladeshis. Compared with professional 
workers, the AOR was 2.16 (95% CI, 1.20–3.89) for transport 
workers, 2.81 (95% CI, 1.32–6.01) for cleaning workers, 3.07 
(95% CI, 1.77–5.32) for technical and construction workers, 
and 3.21 (95% CI, 1.32–7.79) for security workers. No associa-
tion was found for age, contact with an infected person, symp-
toms in the 2 weeks preceding the survey, symptoms requiring 
medical attention, or symptoms requiring hospitalization.
A total of 2092 CMWs consented to PCR testing, of whom 233 
had a positive result—a PCR positivity rate of 11.3% (95% CI, 
9.9–12.8%) (Table 2). PCR cycle threshold (Ct) values ranged from 
15.0 to 38.9, with a median of 27.6 (Figure 1). The Ct value was ≥30 
in 41.6% of PCR-positive CMWs, suggesting no active infection 
[25, 26]. PCR positivity was independently associated with nation-
ality, geographic location (QRCS center), occupation, contact with 
an infected person, and reporting 2 or more symptoms in the 2 
weeks preceding the survey in the multivariable regression anal-
ysis, but no association was found for the other variables (Table 2).
Table 3 summarizes the key SARS-CoV-2 epidemiological 
measures assessed in this study. Infection positivity (antibody 
and/or PCR positive during the study) was assessed at 60.6% (95% 
CI, 58.6%–62.5%). Of the 1427 antibody-positive CMWs, 131 had 
a laboratory-confirmed PCR-positive result for SARS-CoV-2 be-
fore this study, corresponding to a diagnosis (detection) rate of 
9.3% (95% CI, 7.9%–11.0%). The median time between the pre-
vious PCR diagnosis and the antibody-positive test was 63 days. 
Meanwhile, 4 out of the 1214 antibody-negative CMWs, 0.4% 
(95% CI, 0.1%–1.0%), had been previously diagnosed with the in-
fection before this study. The median time between the previous 
PCR diagnosis and the antibody-negative test was 28 days. The Ct 
values and PCR diagnosis date for these individuals were 16.0 on 
July 23, 22.3 on July 25, 22.8 on June 6, and 28.3 on May 2, 2020, 
suggesting that the recency of the infection may explain the lack of 
detectable antibodies for 2 of these 4 individuals.
Out of the total of 1590 participants with laboratory-
confirmed infection (antibody and/or PCR positive), 7 have 
ever had or progressed to a severe infection (prior, during, or 
after this study) and 1 has ever had or progressed to a critical 
infection, as per WHO criteria [24]—an infection severity rate 
of 0.5% (95% CI, 0.2%–1.0%). All severe and critical infections 
were hospitalized but cleared their infection; no COVID-19 
deaths have been recorded.
DISCUSSION
The above results indicate that the CMW population—a popu-
lation that constitutes 60% of the population of Qatar—appears 
to be at or not far from the herd immunity threshold for the 
SARS-CoV-2 variants circulating in Qatar at the time of this 
study. Seroprevalence was ~60% in 3 geographic regions, and 
only lower in Doha East, at 43%. This is to our knowledge the 
first such evidence for herd immunity, or being near herd im-
munity, in a majority segment of the population in any country. 
This conclusion is supported by the fact that no major infection 
cluster has been identified in any CMW community in Qatar 
for several months up to the end of 2020, despite the progres-
sive easing of the social and physical distancing restrictions 
since June 15, 2020 [27]. Meanwhile, large clusters of infection 
were common in such CMW communities before, around, and 
shortly after the epidemic peak toward the end of May 2020.
A level of about 60%–70% infection prevalence to reach 
herd immunity is in concordance with that predicted using the 
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“classical” formula for herd immunity of ∼ 1 − 1/R0 [28, 29], 
with R0, the basic reproduction number, being in the range of 
2.5–4 [30, 31]. This, however, does not support other evidence 
arguing that herd immunity for SARS-CoV-2 infection could 
be reached (without vaccination) at infection levels as low as 
15%–20% [32]. Our findings suggest that herd immunity may 
not be reached before at least half of the population has been 
infected, even in the presence of heterogeneity in the social 
contact rate in a given population [10, 29, 32].
A key finding of this study is the low SARS-CoV-2 infec-
tion severity rate found in this (relatively young) population, 
where only 1 in every 200 infections was ever severe or crit-
ical as per the WHO infection severity classification [24]. 
This outcome agrees with the findings of 2 other studies from 
Qatar, where the infection severity rate has been estimated at 
0.25% (95% CI, 0.11%–0.49%) based on antibody and/or PCR 
laboratory-confirmed infections [10] and at 0.37% (95% CI, 
0.37%–0.38%) based on mathematical modeling of the epi-
demic in the total population [33]—compared with 0.50% (95% 
CI, 0.22%–0.99%) in this study. These rates are substantially 
lower than those estimated elsewhere [34], often using early 
epidemic data, possibly because of insufficient accounting for 
the large denominator of undiagnosed asymptomatic or mild 
infections in young persons. These rates are also unlikely to 
be explained by lower comorbidity levels as disease conditions 
such as obesity, diabetes, and hypertension are at relatively high 
prevalence in Qatar [35–38], comparable to what is seen in de-
veloped nations.
Notably, despite the large epidemic in Qatar, only 236 
COVID-19 deaths have been registered as of November 21, 
2020 [5], indicating also a substantially lower infection fatality 
rate compared with earlier studies [34, 39–41]. An analysis 
of the severity and fatality of SARS-CoV-2 infection in Qatar 
suggested the young age structure of the population, potential 
cross-reactivity to circulating “common cold” coronaviruses, 
and high-quality standard of health care as reasons behind the 
low severity [33].
Though the infection was pervasive in this population, there 
were still some differences in past or current infection preva-
lence by nationality, catchment area/geographic location (QRCS 
center), educational attainment, and occupation (Tables 1 and 
2). Given the totality of evidence on the Qatar epidemic [7, 10, 
27, 33, 42], these differences may be explained by the nature of 
the shared accommodation (size and density), clustering of so-
cial networks by language and/or national background [7], oc-
cupational exposures (such as for drivers) [7], or differences in 
epidemic intensity in different parts of Qatar. Meanwhile, there 
were no differences in infection prevalence by age.
The study had other notable findings. The study design al-
lowed an empirical estimation of the diagnosis (detection) 












PCR Ct value among PCR-positive craft and manual workers
30 35 40
Figure 1. Distribution of PCR Ct values among CMWs identified as SARS-CoV-2 
PCR positive during the study period. Abbreviations: CMWs, craft and manual 
workers; Ct, cycle threshold; PCR, polymerase chain reaction; SARS-CoV-2, severe 
acute respiratory syndrome coronavirus 2.
Table 3. Key SARS-CoV-2 Epidemiological Measures Assessed in the Study
Epidemiological Measure Sample (Denominator) Positive for Outcome (Numerator) Estimate (95% CI), %a
Antibody positivity (seropositivity) prevalence 2641 1427 55.3 (53.3–57.3)
PCR positivity prevalence 2092b 233 11.3 (9.9–12.8)
Infection (antibody and/or PCR) positivity prevalence 2641 1571 60.6 (58.6–62.5)
Infection diagnosis ratec 1427 131 9.3 (7.9–11.0)
Antibody-negative CMWs previously PCR-diagnosed with SARS-
CoV-2 infection
1214 4 0.4 (0.1–1.0)
Infection severity rated 1590e 8f 0.5 (0.2–1.0)
Abbreviations: CMWs, craft and manual workers; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
aEstimates weighted by age, nationality, and center.
bOnly 2092 persons consented to have nasopharyngeal and oropharyngeal swabs.
cProportion of antibody-positive CMWs with a prior SARS-CoV-2 laboratory-confirmed PCR diagnosis.
dNumber of infections ever severe or critical per World Health Organization criteria over total number of laboratory-confirmed infections (antibody and/or PCR positive).
eThis number includes also 4 persons who were antibody negative and PCR negative at the time of the survey but had a PCR-positive result before the survey. This number also includes 
15 persons who were antibody negative and PCR negative at the time of the survey but had a PCR-positive result subsequent to the survey at the time of data linking and analysis (October 
7, 2020).
fSeven participants in this study had ever had (or progressed to) a severe infection and 1 had a critical infection per World Health Organization infection severity classification [24] at the time 
of data linking and analysis (October 7, 2020).
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cases, only 9.3% (95% CI, 7.9%–11.0%) had a documented 
PCR-confirmed infection before antibody testing in this study, 
indicating that 9 in every 10 infections were never diagnosed, a 
finding that agrees with estimates from other settings [39, 43–
46]. This outcome supports that most infections were asymp-
tomatic or too mild to be diagnosed, in line with findings of 
a PCR community survey conducted earlier in Qatar in which 
58.5% of those who were PCR positive reported no symptoms 
in the 2 weeks preceding the survey [7]. Another finding of the 
present study is that reporting of 2 or more symptoms was pre-
dictive of PCR positivity, but not reporting of only 1 symptom 
(Table 2), a similar finding to that of the earlier PCR community 
survey [7]. Lastly, a high proportion of those testing PCR posi-
tive had a Ct value >30, suggesting that nearly half of the PCR-
positive CMWs may have acquired their infection 2–6 weeks 
earlier, given the common presence of prolonged PCR positivity 
in infected persons [25, 26].
This study had limitations. While the study design was in-
tended to be based on probability-based sampling of the total 
CMW population in Qatar, operational challenges and time 
constraints forced instead a systematic sampling of QRCS at-
tendees supplemented with probability-based weights to gen-
erate an estimate that is representative of the wider CMW 
population. To ensure representation of small age–nationality 
strata (such as younger persons of specific nationalities), toward 
the end of the study, all attendees in these strata (not only every 
fourth attendee) were approached to participate. Operational 
challenges made it also difficult to track and maintain con-
sistent logs of the response rate by the nurses in these QRCS 
centers; thus an exact estimate of the response rate could not 
be ascertained, though it was estimated at >90% for antibody 
testing and at >70% for PCR testing. An informed consent was 
obtained from all participants, and thus the purpose of the 
study could not be masked. However, with only 9.3% of those 
testing antibody-positive having a record of prior infection, it is 
unlikely that a previous diagnosis could have appreciably biased 
participation in the study.
While it is possible that the recruitment scheme may have 
affected the generalizability of study findings, this is less likely 
considering that CMWs attend these centers for a range of serv-
ices beyond illness such as periodic health certifications, vac-
cinations, refill medications for chronic diseases, and pretravel 
PCR testing, and that the study’s primary outcome was 
seroprevalence—a marker of past rather than recent infection. 
Nevertheless, these limitations may have introduced selection 
bias for specifically the assessed PCR positivity prevalence and 
infection severity rate toward higher values, as participants may 
still have attended the QRCS centers because of current infec-
tion symptoms.
The laboratory methods were based on high-quality and val-
idated commercial platforms, such as the Roche platform used 
for the serological testing [19, 47], one of the best available and 
most used and investigated commercial platforms with a speci-
ficity ≥99.8% [19, 48] and a sensitivity ≥95% [7, 47]. Factoring 
the less-than-perfect sensitivity and specificity [49] would have 
increased the measured antibody positivity prevalence to 58.1% 
instead of 55.3%. History of SARS-CoV-2 testing, hospitaliza-
tion, and death were extracted through linking participants’ re-
cords to the national, centralized, and fully integrated digital 
health information platforms, and thus it is unlikely that cases/
events were missed.
In conclusion, 6 in every 10 CMWs have already been infected 
with SARS-CoV-2, suggesting that this population is at or not far 
from herd immunity for the SARS-CoV-2 variants circulating 
in Qatar at the time of this study. While the prevalence of past 
or current infection was high, infection severity was low, with 
only 1 in every 200 infections progressing severe or critical dis-
ease. Indeed, most infections must have been asymptomatic or 
too mild to be diagnosed, as only 1 in every 10 antibody-positive 
persons had a prior PCR-confirmed SARS-CoV-2 diagnosis.
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